TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23080326

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 119
Study: 20188348

Group type: EXPERIMENTAL
Intervention: Posttraumatic Avoidance Behaviour Questionnaire (PABQ)
Number of subjects: 437
Study: 18682739

Group type: EXPERIMENTAL
Intervention: 8-week primaquine (PQ) regimen (0.75 mg/kg/week)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 14-day primaquine (PQ) regimen (0.5 mg/kg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (once weekly 8-week)
Number of subjects: 200
Study: 16374224

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (FS)
Number of subjects: 6961

Group type: COMPARATOR
Intervention: Control group (not invited to screening)
Number of subjects: 6961
Study: 14673492

Group type: EXPERIMENTAL
Intervention: Learning through research papers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textbook instruction
Number of subjects: 0
Study: 10809915

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum toxin (Botox(R)) 2 U/4 cm2
Number of subjects: 28
Study: 9863158

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg.d‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (100 mg)
Number of subjects: 0
Study: 1912368

Group type: EXPERIMENTAL
Intervention: MMC+FT+Bestatin
Number of subjects: 96

Group type: COMPARATOR
Intervention: MMC+FT
Number of subjects: 96
Study: 6125636

Group type: EXPERIMENTAL
Intervention: No-added-sodium diet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (standard medication)
Number of subjects: 90
Study: 31868978

Group type: EXPERIMENTAL
Intervention: PM-AM-PM group (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: AM-PM-AM group (n = 13)
Number of subjects: 26
Study: 30723183

Group type: EXPERIMENTAL
Intervention: Radiographic emphysema
Number of subjects: 16624

Group type: COMPARATOR
Intervention: No radiographic emphysema
Number of subjects: 16624
Study: 28402208

Group type: EXPERIMENTAL
Intervention: Dynamic scheduling procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly assigned appointments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniformly assigned appointments
Number of subjects: 0
Study: 27494089

Group type: EXPERIMENTAL
Intervention: Ofatumumab plus chlorambucil (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle; ofatumumab: Cycle 1: 300 mg on Day 1 and 1000 mg on Day 8; subsequent cycles: 1000 mg Day 1 for 3-12 cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil monotherapy (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle)
Number of subjects: 0
Study: 24120714

Group type: EXPERIMENTAL
Intervention: prednisolone 2.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: prednisolone 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: prednisolone 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: prednisolone 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: prednisolone 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACTH stimulation tests
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: metyrapone test
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: markers of bone turnover
Number of subjects: 60
Study: 22688509

Group type: EXPERIMENTAL
Intervention: LAM+ADV
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 27

Group type: COMPARATOR
Intervention: ADV
Number of subjects: 27
Study: 19898642

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (HbA(1c) < 6%) in ACCORD trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive glucose control in general (ACCORD, ADVANCE, VADT, UKPDS post-trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term glycemic control (UKPDS post-trial)
Number of subjects: 0
Study: 17572346

Group type: EXPERIMENTAL
Intervention: Atropine 1% solution (N = 134)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Patching (N = 148)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Atropine only (n = 41)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Patching only (n = 64)
Number of subjects: 282
Study: 14747205

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels in boys aged 15-18 years
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels in girls aged 11-14 years
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Testosterone levels in boys
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Insulin resistance and beta-cell function
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adiponectin levels during puberty in boys
Number of subjects: 500
Study: 11446314

Group type: EXPERIMENTAL
Intervention: SF-36 m
Number of subjects: 300

Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 300
Study: 9509783

Group type: EXPERIMENTAL
Intervention: Parallel‐sided bars (rigid joint)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oval straight bars (resilient joint)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7578765

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg IV every 8 hours
Number of subjects: 235

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg IV every 6 hours
Number of subjects: 235
Study: 2595265

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 3:1 ratio
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 1:3 ratio
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unoperated group
Number of subjects: 36
Study: 1101611

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline 5 mug/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with adrenaline 5 mug/ml
Number of subjects: 0
Study: 31062079

Group type: EXPERIMENTAL
Intervention: Tea catechin-enriched beverage (611 mg catechins, 88 mg caffeine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo beverage (0 mg catechins, 81 mg caffeine)
Number of subjects: 30
Study: 30662324

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: LAM and ADV combination therapy (Control)
Number of subjects: 360
Study: 29223429

Group type: EXPERIMENTAL
Intervention: Conservatively managed non-infarct-related artery lesions
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Risk score model based on clinical and angiographic characteristics
Number of subjects: 664
Study: 26341167

Group type: EXPERIMENTAL
Intervention: Surgical Baseball Cards (SBCs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no SBCs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: SBCs
Number of subjects: 162
Study: 24185842

Group type: EXPERIMENTAL
Intervention: Cardiovascular plus resistance training protocol (CRT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-intensity strength training protocol (HIST)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 75
Study: 20570319

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NFT) prophylaxis 100 mg b.i.d. for 7 days preoperatively
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard perioperative antibiotic prophylaxis
Number of subjects: 101
Study: 19917943

Group type: EXPERIMENTAL
Intervention: Short stitch length (<10 mm from the wound edge)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Long stitch length
Number of subjects: 737
Study: 16476929

Group type: EXPERIMENTAL
Intervention: DCA (25 mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12756868

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 10
Study: 11083552

Group type: EXPERIMENTAL
Intervention: Recombinant human PDGF-BB (rhPDGF-BB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28
Study: 9279344

Group type: EXPERIMENTAL
Intervention: TUT-7 (menogaril) at 75 or 100 mg/body/day for 7 or 14 days with two-week drug withdrawal
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: TUT-7 (menogaril)
Number of subjects: 165
Study: 8443037

Group type: EXPERIMENTAL
Intervention: MDL 72394 (MAO‐A inhibitor) 16 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MDL 72974A (MAO‐B inhibitor) 12 mg
Number of subjects: 9
Study: 31288610

Group type: EXPERIMENTAL
Intervention: Witnesses of childhood violence
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Female witnesses
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Male witnesses
Number of subjects: 907

Group type: COMPARATOR
Intervention: Non-witnesses
Number of subjects: 907
Study: 28814150

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study: 27793175

Group type: EXPERIMENTAL
Intervention: Luminor® paclitaxel‐coated drug‐eluting balloon (DEB) catheter
Number of subjects: 172

Group type: COMPARATOR
Intervention: Noncoated, plain old balloon angioplasty (POBA) catheter
Number of subjects: 172
Study: 24322377

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS) combination chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 101
Study: 22283861

Group type: COMPARATOR
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in late responders (LR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in early responders (ER)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR)
Number of subjects: 60
Study: 20334686

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (diet, physical activity, behavioral therapy)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 324
Study: 18674465

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (UFH)
Number of subjects: 20
Study: 16171631

Group type: EXPERIMENTAL
Intervention: Mosaic-type osteochondral autologous transplantation (OAT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 60
Study: 12134175

Group type: EXPERIMENTAL
Intervention: 6 months antiepileptic drug therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2 years antiepileptic drug therapy
Number of subjects: 73
Study: 10212074

Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/kg of body weight/day up to a maximum of 400 IU/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vitamin D 960 IU/day
Number of subjects: 39
Study: 7995773

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant interferon gamma (r IFN-gamma) at doses of 0.1, 0.2, 0.6, 1.8, or 5.4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant interferon gamma (r IFN-gamma)
Number of subjects: 8
Study: 2186320

Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Epirubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 224

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Patients with more than one organ site involved
Number of subjects: 224

Group type: COMPARATOR
Intervention: Patients who had previously received adjuvant chemotherapy
Number of subjects: 224
Study: 406624

Group type: EXPERIMENTAL
Intervention: Marijuana low dose with aversive noise
Number of subjects: 96

Group type: COMPARATOR
Intervention: Marijuana low dose without aversive noise
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Marijuana high dose with aversive noise
Number of subjects: 96

Group type: COMPARATOR
Intervention: Marijuana high dose without aversive noise
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31337400

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGb)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Joint torque biofeedback (Rb)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lokomat training (both biofeedback types)
Number of subjects: 12
Study: 28528567

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) consisting of 12 individual sessions with a psychologist over 16 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control treatment consisting of three consultations with an MS nurse over 16 weeks
Number of subjects: 91
Study: 25539660

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 23329565

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in AGA infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21472469

Group type: EXPERIMENTAL
Intervention: Multilevel surgery with tonsillectomy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Multilevel surgery without tonsillectomy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Preoperative AHI, BMI, age as predictors
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Success according to Sher criteria
Number of subjects: 144
Study: 19757514

Group type: EXPERIMENTAL
Intervention: 2 l polyethylene glycol (group A)
Number of subjects: 201

Group type: COMPARATOR
Intervention: 4 l polyethylene glycol (group B)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study: 16964276

Group type: EXPERIMENTAL
Intervention: Outreach placement (5-week block)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional hospital-based training
Number of subjects: 49
Study: 15455188

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (switched to risedronate)
Number of subjects: 164
Study: 11178303

Group type: EXPERIMENTAL
Intervention: OPCAB using the Octopus II stabilizing system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional CABG with CPB
Number of subjects: 26
Study: 9306147

Group type: EXPERIMENTAL
Intervention: Stress MIBI SPECT imaging
Number of subjects: 235
Study: 8294198

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2963034

Group type: EXPERIMENTAL
Intervention: Zimelidine (200 mg/day orally)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day orally)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day orally)
Number of subjects: 22
Study: 31872245

Group type: EXPERIMENTAL
Intervention: 4 g daily of icosapent ethyl
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Statin therapy (control)
Number of subjects: 8179
Study: 29486741

Group type: EXPERIMENTAL
Intervention: Intensive Home Treatment (IHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 0
Study: 27411773

Group type: EXPERIMENTAL
Intervention: Patient-centered CPR education (PCE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (video-based CPR self-education and booklets)
Number of subjects: 54
Study: 24647395

Group type: EXPERIMENTAL
Intervention: 2 continuous portions (2C)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 2 intermittent portions (2I)
Number of subjects: 65
Study: 22947291

Group type: EXPERIMENTAL
Intervention: Off-flap epi-LASIK with mitomycin C (MMC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: On-flap epi-LASIK with mitomycin C (MMC)
Number of subjects: 18
Study: 20922865

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with lower preoperative hemoglobin levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with longer duration of surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall study conclusion
Number of subjects: 80
Study: 18696748

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study: 16182714

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 2
Study: 12619939

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 10574619

Group type: EXPERIMENTAL
Intervention: rHuIL-10 at a dose of 4 or 8 microg/kg/day as a single daily subcutaneous injection for 28 days
Number of subjects: 16
Study: 9064111

Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (one dissolve-in-the-mouth tablet in the morning and one in the evening)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cacit 1000 (one effervescent tablet)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (two tablets in a single dose)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (two doses)
Number of subjects: 22
Study: 1883790

Group type: EXPERIMENTAL
Intervention: Birth‐EZ chair
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Conventional delivery bed
Number of subjects: 1250
Study: 6847466

Group type: EXPERIMENTAL
Intervention: Mild silver protein solution (Argyrol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Untreated eye (control)
Number of subjects: 32
Study: 30821654

Group type: EXPERIMENTAL
Intervention: Micronutrients (vitamins and minerals)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Micronutrients
Number of subjects: 27
Study: 30033681

Group type: EXPERIMENTAL
Intervention: using tissue spreader technique (A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: using skin hooks technique (B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: using sharp scissor technique (C)
Number of subjects: 10
Study: 28906405

Group type: EXPERIMENTAL
Intervention: Quadripolar leads (QUAD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional bipolar leads (CONV)
Number of subjects: 52
Study: 26347970

Group type: EXPERIMENTAL
Intervention: 1-hour transcutaneous tibial nerve stimulation for 6 weeks (total of 12 treatments)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4-hour transcutaneous tibial nerve stimulation for 6 weeks (total of 12 treatments)
Number of subjects: 43
Study: 24247188

Group type: EXPERIMENTAL
Intervention: Pycnogenol 100 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pycnogenol 150 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study: 21661618

Group type: EXPERIMENTAL
Intervention: Intensive intervention (bedside counselling, take-home materials, 7 post-discharge telephone counselling calls over 2 months)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Brief intervention (advice and pamphlets)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: No pharmacotherapy
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: With pharmacotherapy
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Patients with CVD
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Patients with other diagnoses
Number of subjects: 616
Study: 19704167

Group type: EXPERIMENTAL
Intervention: Untreated (treatment-naive) group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 3TC-resistant group
Number of subjects: 159
Study: 16722839

Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Number of subjects: 12
Study: 14572305

Group type: COMPARATOR
Intervention: 400 mg of oral magnesium citrate every 8 h for 5 days (prevention trial)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 4 g of intravenous magnesium sulphate (treatment trial)
Number of subjects: 61
Study: 11262213

Group type: EXPERIMENTAL
Intervention: hPIV3 maternal antibody
Number of subjects: 0
Study: 9151912

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with epirubicin (40 mg/m2 intra-arterial at 1 month after resection, followed by intravenous administration of 40 mg/m2 every 3 months for 2 years) and carmofur (300 mg/d orally for 24 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group undergoing resection only
Number of subjects: 57
Study: 8486887

Group type: EXPERIMENTAL
Intervention: Non-strenuous physical exercise (15 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (watched a video of similar exercises for 15 minutes)
Number of subjects: 20
Study: 3122628

Group type: EXPERIMENTAL
Intervention: TTS NG 10 mg/24 h
Number of subjects: 20
Study: 29439289

Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 542

Group type: COMPARATOR
Intervention: ADA (reference adalimumab)
Number of subjects: 542

Group type: COMPARATOR
Intervention: ADA/SB5 group (switched from ADA to SB5)
Number of subjects: 542

Group type: COMPARATOR
Intervention: ADA/ADA group (continued ADA)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: SB5 group (continued SB5)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 542
Study: 28789663

Group type: EXPERIMENTAL
Intervention: Sodium nitrate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26536702

Group type: EXPERIMENTAL
Intervention: Golden voice capsule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Golden voice capsule and omeprazole
Number of subjects: 60
Study: 24011069

Group type: EXPERIMENTAL
Intervention: LY2405319 (3, 10, or 20 mg daily for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21170803

Group type: EXPERIMENTAL
Intervention: One-arm maximal strength training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23